Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries).

Synthetic organic reactions are a fundamental enabler of small-molecule drug discovery, and the vast majority of medicinal chemists are initially trained--either at universities or within industry--as synthetic organic chemists. The sheer breadth of synthetic methodology available to the medicinal chemist represents an almost endless source of innovation. But what reactions do medicinal chemists use in drug discovery? And what criteria do they use in selecting synthetic methodology? Why are arrays (small focused libraries) so powerful in the lead-optimization process? In this Minireview, we suggest some answers to these questions and also describe how we have tried to expand the number of robust reactions available to the medicinal chemist.

[1]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[2]  M. Hack,et al.  Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity. , 2006, Bioorganic & medicinal chemistry letters.

[3]  S. Free,et al.  A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. , 1964, Journal of medicinal chemistry.

[4]  Visakan Kadirkamanathan,et al.  Analysis of Neighborhood Behavior in Lead Optimization and Array Design , 2009, J. Chem. Inf. Model..

[5]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[6]  R. Stoffel,et al.  Discovery and optimization of (R)-prolinol-derived agonists of the Growth Hormone Secretagogue receptor (GHSR). , 2008, Bioorganic & medicinal chemistry letters.

[7]  Philip Smith,et al.  Lead optimization in 12 months? True confessions of a chemistry team. , 2001, Drug discovery today.

[8]  M. Waring.  Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[9]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[10]  A. J. Blake,et al.  The rhodium carbene route to oxazoles: a remarkable catalyst effect. , 2009, Chemical communications.

[11]  M. Gleeson.  Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.

[12]  Adam Nelson,et al.  Convergent synthesis of dihydroquinolones from o-aminoarylboronates , 2009 .

[13]  J. S. Carey,et al.  Analysis of the reactions used for the preparation of drug candidate molecules. , 2006, Organic & biomolecular chemistry.

[14]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[15]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[16]  S. Macdonald,et al.  A direct route to triazole boronic esters and their application in the synthesis of small molecule arrays , 2009 .

[17]  Stuart L Schreiber,et al.  Towards the optimal screening collection: a synthesis strategy. , 2008, Angewandte Chemie.

[18]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[19]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[20]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[21]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[22]  S. Schreiber,et al.  Der optimale Molekülsatz für Screening‐Anwendungen: eine Synthesestrategie , 2008 .

[23]  Adam Nelson,et al.  Convergent, regiospecific synthesis of quinolines from o-aminophenylboronates. , 2008, Organic letters.

[24]  J. Kramer,et al.  The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates , 2007, Nature Reviews Drug Discovery.